Mithra Pharmaceuticals SA (0R91.IL)

0.2215 0.0000 (0.00%) At close: 05:11PM BST

Mithra Pharmaceuticals SA

Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 270

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David Horn Solomon M.D.	Chief Exec. Officer	N/A	N/A	1960
Mr. Christophe Marechal	Chief Financial Officer	N/A	N/A	N/A
Mr. Xavier Paoli M.Sc.	Chief of Operations	N/A	N/A	N/A
Dr. Graham K. Dixon Ph.D.	Chief Scientific Officer	N/A	N/A	1961
Fanny Storms	Compliance Officer	N/A	N/A	N/A
Mr. Jean-Manuel Fontaine	Chief Commercial & External Affairs Officer	N/A	N/A	N/A
Prof. Jean-Michel Foidart M.D., Ph.D.	Pres of the Scientific Advisory Board & Exec. Director	7.12k	N/A	N/A
Fanny Rozenberg	Sec. of the Board	N/A	N/A	N/A

Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Corporate governance

Mithra Pharmaceuticals SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.